Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients

Pharmacotherapy

Volumn 34, Issue 1, 2014, Pages 28-35

  Sturm, Ashley W ^a   Allen, Nichole ^a   Rafferty, Kelly D ^a   Fish, Douglas N ^b   Toschlog, Eric ^c   Newell, Mark ^c   Waibel, Brett ^c  

^a VIDANT MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Antibiotic dosing; Infectious disease; Morbidly obese; Obese; Pharmacodynamics; Pharmacokinetics; Piperacillin tazobactam

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM;

ABSENCE OF SIDE EFFECTS; ADULT; APACHE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN; INTENSIVE CARE; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; MORBID OBESITY; OPEN STUDY; PHARMACODYNAMICS; PROSPECTIVE STUDY; SEPSIS; STEADY STATE; SURGICAL PATIENT; TEACHING HOSPITAL; VENTILATOR ASSOCIATED PNEUMONIA;

ANTIBIOTIC DOSING; INFECTIOUS DISEASE; MORBIDLY OBESE; OBESE; PHARMACODYNAMICS; PHARMACOKINETICS; PIPERACILLIN-TAZOBACTAM;

AGED; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OBESITY, MORBID; PENICILLANIC ACID; PIPERACILLIN; PROSPECTIVE STUDIES;

EID: 84898020642     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1324     Document Type: Article

References (18)

1. Erstand BL. Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Med 2004;30: 18-32.
2. Janson B, Thursky K. Dosing of antibiotics in obesity. Curr Opin Infect Dis 2012;25: 634-49.
3. Tam VH, Gamez EA, Weston JS, et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 2008;46: 862-7.
4. Jeffres MN, Barclay SM, Daly MW, et al. Impact of body size descriptors on initial treatment response and thirty-day mortality in patients with gram-negative infections. J Appl Res Clin Exp Ther 2012;12: 30-7.
5. Li C, Kuti JL, Nightingale CH, et al. Population pharmacokinetic and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 2005;56: 388-95.
6. Zakrison TL, Hille DA, Namias N. Effects of body mass on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillin-tazobactam. Surg Infect (Larchmt) 2012;13: 38-42.
7. Chetham SC, Fleming MR, Healy DP, et al. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. Int J Antimicrob Agents 2013;41: 52-6.
8. Hites M, Taccone FS, Wolff F, et al. Case-control study of drug monitoring of ß-lactams in obese critically ill patients. Antimicrob Agents Chemother 2013;57: 708-13.
9. Newman D, Scheetz MH, Adeyemia OA, et al. Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual. Ann Pharmacother 2007;41: 1734-9.
10. Deman H, Verhaegen J, Willems L, Spriet I. Dosing of piperacillin/ tazobactam in a morbidly obese patient. J Antimicrob Chemother 2012;67: 782-3.
11. Demirovic JA, Pai AB, Pai MP. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm 2009;66: 642-8.
12. Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents 2005;25: 62-7.
13. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. Document M100-S22. Wayne, PA; CSI; 2012.
14. Winter ME. Part I. Basic principles. In: Winter M, ed. Basic clinical pharmacokinetics. Baltimore, MD: Lippincott Williams & Wilkins; 2004: 19-73.
15. Wyeth Pharmaceuticals Inc. (May 2012) ZosynTM US Product Information, Philadelphia, PA. Accessed December 2012.
16. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010;49: 71-87.
17. Lodise TP, Lomaestro BM, Drusane GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on b-lactam antibiotics. Pharmacotherapy 2006;26: 1320-32.
18. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009;37: 840-51.